BBTV

About Us

latest videos

Vaccinogen Presentation at Cancer Immunotherapy Conference

Vaccinogen Logo

Featuring : Michael G. Hanna Jr., PhD, Founder and Chairman, Vaccinogen Inc.
This corporate presentation was recorded during “Cancer Immunotherapy: A Long Awaited Reality”, a conference hosted by BioBusiness.TV and MD Becker Partners on October 21st, 2010, at the New York Academy of Medicine.

Genzyme / Sanofi : Why The Price Isn’t Quite Right

Biotech In the Money with Marina Bozilenko
  1. Genzyme / Sanofi : $75-80 per share, The Big Win-Win
  2. Biosimilars, the Abbreviated BLA, and TEVA’s Response Letter
  3. Hepatitis C News to be Expected in November (AASLD) – VRTX, MRK, BMY, GILD, JNJ
  4. Novartis’ Multiple Sclerosis Pill (Gilenya) Joepardizing the Biogen Idec Franchise?
  5. State of the Markets: “Healthiest Time for Mid-Caps in 10 years.”

AMRS – Amyris CEO John G. Melo Interviewed by Boonsri Dickinson

amyris 90x90
  1. Reprogramming yeast to make high value carbons for use in consumer goods and energy markets
  2. Amyris’ IP portfolio and Sanofi’s no-fee license for malaria
  3. A platform and a product that will compete with Dupont and BSF while being managed like a jazz band
  4. Bolt-on facilities allow focused effort and capital on fermentation, not agriculture
  5. Business model : low cost, large scale, long demand
  6. Near term milestones and 5-10 year vision

Understanding the FDA – Biotech In the Money

Biotech In the Money with Marina Bozilenko
  1. Why the Paradigm Shift at the FDA, over the Past 5 Years?
  2. Is Anything Binding With the FDA Anymore, or Are Companies Just Not Listening?
  3. Chronic Disease vs. Critical Needs: the FDA Fast Track, and Recourses for Companies
  4. Biosimilars are Without a Champion at the FDA
  5. FDA Very Actively Enforcing Compliance Regulation
  6. If You Had Unlimited Powers, How Would You Reform the FDA?
  7. Combination Therapy in the Eyes of the FDA. Can We Let FDA Off the Hook? The System Return to a More Rational Process

VICL – Vical CEO Vijay Samant interviewed by Stephen Willey

Wall Street on BioBusiness.TV
  1. DNA Vaccines, a Fast and Efficient ‘Plug-N-Play’ Technology
  2. Allovectin-7, a Phase 3 Cancer Immunotherapy for Head & Neck Tumors
  3. TransVax, a Phase 2 DNA Vaccine to Prevent Cytomegalovirus (CMV) Reactivation
  4. Vical’s Speed and Adaptability Play on Pandemic Influenza Appeals to Department of Defense for Military Vaccines
  5. Vical Licensors, Sanofi and Angios, in Phase 3 Trials on Multi-Billion Dollar PAD Market

Hepatitis C, Neurology, Healthcare Reform, Genetic Testing – Biotech in the Money

Biotech In the Money with Marina Bozilenko
  1. Meeting Update: Hepatitis C – 2010 EASL
  2. Meeting Update: Neurology – 2010 AAN
  3. Obama’s Healthcare Reform, Good for Pharma, Biotech, and Generics?
  4. Implications of the MYGN Suit, the Future of Genetic Testing
  5. Status of the Financial Markets, IPOs and FOs in the YTD

Multiple Sclerosis Breakthrough, Dr. Laurence Steinman

Nature Medicine and BioBusiness.TV present Science Breakthrough
  1. New Blood Test Predicts Efficacy of Multiple Sclerosis Drug Beta Interferon
  2. 1-in-4 MS Patients Could Be IL17 Non-Responders to the $4Bn Revenue Beta Interferon Drug
  3. IL17 to Multiple Sclerosis as KRAS to Colon Cancer?
  4. When Will the 300,000+ Patients on Beta Interferon Benefit From Dr Steinman’s Breakthrough Study?
  5. Impact of IL17 on MS Drugs in the Pipeline, and Potential Applicability in PML

IPO Review, OSIP, Medivation, Xenoport, Genzyme – Biotech in the Money

Biotech In the Money with Marina Bozilenko
  1. The OSIP / Astellas Saga
  2. The 2010 Biotech IPO Review, 1st Quarter
  3. Medivation’s Phase 3 is a Total Bust. Will Dimebon get a Second Life?
  4. Xenoport’s Phase 3, Also a Bust. An Eleventh-hour FDA Decision?
  5. Good News of the Month : Acorda and Viropharma, Stories with Upside
  6. Big Pharma’s Cancer Setbacks, Arrr You Hungry for More Biotech?
  7. Shareholder Activism : What Carl Icahn Can and Cannot Do with Genzyme
  8. Next Month in Biotech, Events to Look Out For

An Interview with Steve Burrill

burrill-6-90
  1. Adapting to Change, an Interview with Steve Burrill
  2. No Real Healthcare Reform, Only Insurance Reform
  3. Financing Biotech in 2010
  4. From Personalized Medicine to Preemptive Medicine
  5. Stem Cells and Other Promising New Technologies
  6. FAST Word Association Game, with Steve Burrill

MYGN – Myriad Genetics CEO Peter Meldrum Interviewed by Charles Duncan

Wall Street on BioBusiness.TV
  1. A Brief History of Myriad Genetics
  2. BRAC Analysis, Myriad Genetics’ Primary Revenue Driver
  3. Is a European Expansion to be Expected from Myriad Genetics? Checklist and Roadmap
  4. Optimal Chemotherapy Dosing with OnDose, from Myriad Genetics
  5. Myriad Genetics’ Latest Diagnostic (PROLARIS) Predicts Prostate Cancer Recurrence.
  6. Patenting Genes: What if the ACLU Wins the Case Against Myriad Genetics?
  7. Financials: How is Myriad Genetics Planning to Return Cash to Investors?
<< Previous12345678910Next >>...Last »

  • Best of the Web

    • Alzheimer's Disease
    • Antibiotic Resistance
    • Cancer Immunotherapy
    • Cell Therapy
    • Hepatitis C
    • LOL
    • Stem Cells
    • - View All -

  • Series

    • The Stem Cell Review
    • Cancer Immunotherapy

  • Shows

    • Biotech in the Money
    • Wall Street On BBTV
    • Science Breakthrough
    • The Jan Buck Show
    • Special Interview
    • Report on Location

  • Corporate Videos

    • 60sec Pitches
    • Investor Presentations
    • Panorama

  • Store

    • Series Sponsorship
    • Corp. Communications
    • DVDs

  • Acknowlegments

    NASDAQ OMX BIO Nature Medicine William Blair Banc of America Cowen Group JMP Securities JP Morgan Ladenburg Thalmann Lazard Capital Markets Piper Jaffrey

  • About the Show


    Wall Street Analysts interviewing Biotech CEOs.

  • ABOUT BIOBUSINESS.TV
  • BioBusiness.TV is the first independent Internet TV Network for biotechnology professionals. We create and syndicate video-based industry focused shows and series that range from scientific breakthroughs, to equity analyst insights, as well as C-level executive and investor interviews on strategy, management, policy, marketing, science and more. We strive to enhance the quality and accessibility of industry video programming, and to deliver information biotechnology professionals can rely on to make sound and informed decisions.
  • PARTNERING WITH BIOBUSINESS.TV
  • If you’ve got great video programs and a growing audience, let BioBusiness.TV help you take it to the next level through our Partner Program. You can reach out to us through our ‘contact us’ page.
  • DISCLAIMER
  • Viewers should verify all claims and do their own due diligence before investing in any securities mentioned on BioBusiness.TV.
  • COPYRIGHT © 2011 BIO BUSINESS TV, INC. All Rights Reserved